Henry Schein（HSIC）株式概要
ヘンリー・シャイン・インクは、世界中の歯科・医科開業医にヘルスケア製品とサービスを提供している。 詳細
HSIC Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Henry Schein, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$74.21 |
| 52週高値 | US$89.29 |
| 52週安値 | US$61.95 |
| ベータ | 0.82 |
| 1ヶ月の変化 | -4.99% |
| 3ヶ月変化 | -6.74% |
| 1年変化 | 3.57% |
| 3年間の変化 | -0.95% |
| 5年間の変化 | -2.41% |
| IPOからの変化 | 1,204.79% |
最新ニュース
Recent updates
分析記事 • May 08
Henry Schein, Inc. Just Recorded A 8.1% EPS Beat: Here's What Analysts Are Forecasting Next
Henry Schein, Inc. ( NASDAQ:HSIC ) shareholders are probably feeling a little disappointed, since its shares fell 5.5...
ナラティブの更新 • Apr 26
HSIC: Improving Dental Demand And Buybacks Are Expected To Support Upside
Narrative Update on Henry Schein The updated analyst price target for Henry Schein reflects a modest upward adjustment in fair value to about $90 per share, as analysts incorporate refreshed models following recent Q4 results, new initiations, and several target raises across the Street. Analyst Commentary Recent research updates on Henry Schein show a mixed but generally constructive tone, with several firms revising models after Q4 results and initial FY26 guidance.ナラティブの更新 • Apr 11
HSIC: Rising Dental Demand And New CEO Transition Are Expected To Support Upside
Henry Schein's updated analyst price target edges slightly lower to about $89, as analysts refine their models following recent Q4 results and revised long-term growth assumptions across the Street. Analyst Commentary Street research around Henry Schein has turned more constructive overall, with several firms updating models following the Q4 print and initial FY26 guidance.ナラティブの更新 • Mar 28
HSIC: Rising Dental Demand And New CEO Are Expected To Support Upside
Narrative Update on Henry Schein The updated analyst price target for Henry Schein edges up to $90.00, reflecting a series of target increases across the Street as analysts factor in better than expected Q4 results, initial FY26 guidance, refreshed models, and improved visibility on growth and end market demand. Analyst Commentary Street research on Henry Schein clusters around higher price targets following Q4 results and initial FY26 guidance, with most firms updating their models and a mix of Outperform, Overweight, Neutral, Hold, and Market Perform ratings.ナラティブの更新 • Mar 13
HSIC: Improving Dental Demand And New CEO Leadership Will Support Upside
The analyst price target for Henry Schein has been raised from $83.21 to $89.79, reflecting updated models that factor in Q4 results, initial FY26 guidance, and what analysts describe as better growth visibility and a more supportive demand backdrop. Analyst Commentary Across the Street, recent research points to a more constructive stance on Henry Schein following Q4 results and initial FY26 guidance, with several firms revising their models and resetting price targets.
新しいナラティブ • Feb 25
Cloud Software And Specialty Products Will Reshape This Healthcare Distributor’s Future Earnings Power
Catalysts About Henry Schein Henry Schein is a global distributor of dental and medical products and services with growing software, specialty and value-added solutions for healthcare providers. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Feb 25
HSIC: Steadier Dental Demand And CEO Transition Will Support Balanced Outlook
Analysts have nudged their fair value estimate for Henry Schein up from $78.14 to $83.21, citing higher Street price targets and commentary about steadier organic growth and improving dental demand as the main supports for the updated view. Analyst Commentary Recent Street research on Henry Schein leans constructive, with several firms lifting price targets and, in one case, upgrading the rating as sentiment around dental demand and organic growth improves.ナラティブの更新 • Feb 10
HSIC: Revised Assumptions And CEO Transition Will Support Balanced Earnings Outlook
Analysts have increased their price target on Henry Schein by US$7, citing updated assumptions around revenue growth, margins, and future P/E levels that contribute to a revised valuation view. Analyst Commentary Recent research behind the US$7 upward move in the price target focuses on refreshed assumptions for Henry Schein’s revenue trajectory, margin profile, and future P/E levels.ナラティブの更新 • Jan 25
HSIC: Q3 Beat And CEO Transition Will Support Range-Bound Earnings Momentum
Narrative Update: Henry Schein The analyst price target for Henry Schein has moved slightly higher by about US$0.50, as analysts point to recent price target increases and a "clean beat" in Q3 that they see as supporting a modestly higher fair value while still viewing the shares as range bound. Analyst Commentary Recent Street commentary on Henry Schein points to a mixed setup, with some bullish analysts nudging price targets higher on the back of Q3 execution and others still reluctant to see a clear path out of the stock's trading range.ナラティブの更新 • Jan 11
HSIC: Q3 Beat And AI Partnerships Will Support Range-Bound Earnings Momentum
Analysts have raised their price target on Henry Schein to US$75 from US$71, citing a clean Q3 earnings beat that they view as supporting the recent share price strength, while also questioning how much further the stock can advance beyond its recent trading range. Analyst Commentary Bullish Takeaways Bullish analysts view the Q3 result as a clean beat, which they see as supporting the recent share price move and giving the higher US$75 target some fundamental backing.ナラティブの更新 • Dec 19
HSIC: Q3 Beat And Buybacks Will Support Range-Bound Earnings Momentum
Analysts have modestly raised their price target on Henry Schein to approximately $75, reflecting a slightly higher fair value and future price-to-earnings multiple following a clean Q3 beat, even as they remain cautious about the stock meaningfully breaking out of its recent trading range. Analyst Commentary Street research following the Q3 report reflects a mix of cautious optimism and ongoing skepticism about Henry Schein's near term upside potential.Seeking Alpha • Dec 05
Henry Schein Can Make Your Portfolio Smile
Summary Henry Schein stands out as the largest global provider of healthcare products and services for office-based dental and medical practitioners, with a strong market share. HSIC continues to deliver solid growth, reporting Q3 revenue up 5.2% year-over-year and improved profitability across all segments, driven by internal growth and targeted programs. Management anticipates ongoing revenue and EBITDA growth, supported by demographic trends, increased healthcare access, and technological advancements like AI in dental care. Shares are attractively valued relative to peers, justifying a soft "Buy" rating for this high-quality industry leader with promising expansion catalysts. Read the full article on Seeking Alphaナラティブの更新 • Dec 05
HSIC: Q3 Beat And Capital Returns Will Support Measured Earnings Momentum
Analysts modestly raised their price target on Henry Schein to $75 from $71, citing a clean Q3 beat that supports recent share gains while still questioning the stock's ability to break out above its historically defined trading range. Analyst Commentary Analysts highlight that the latest quarter delivered a clean beat versus expectations, reinforcing confidence in Henry Schein's ability to execute on its operating plan despite macro and industry headwinds.ナラティブの更新 • Nov 20
HSIC: Operational Improvements and Automation Are Expected to Support Earnings Momentum
Analysts have increased their price target for Henry Schein from $75 to $77, citing expectations for moderate improvements in revenue growth and future earnings. They also pointed to optimism driven by recent operating performance and strategic initiatives.ナラティブの更新 • Nov 05
HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook
Henry Schein’s analyst price target has increased from $73.23 to $75.15 per share, reflecting analysts’ confidence in improving margins and strategic initiatives following recent earnings results. Analyst Commentary Following the company's recent performance and updated guidance, research analysts have issued new commentary highlighting both upward momentum and remaining concerns regarding Henry Schein's outlook.分析記事 • Aug 08
Henry Schein, Inc. Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
NasdaqGS:HSIC 1 Year Share Price vs Fair Value Explore Henry Schein's Fair Values from the Community and select yours...Seeking Alpha • Mar 11
Henry Schein Looks Bullish (Technical Analysis)
Summary HSIC shows bullish price action, momentum, volume, and relative strength, making it an attractive investment with a 2.6 reward-to-risk ratio. The stock is in an uptrend, trading above its 30-week EMA, and has bullish short-term and long-term momentum as indicated by the PPO. Institutional buying supports bullish volume trends, and HSIC has been outperforming the S&P 500 since December 2024. Despite recent earnings not meeting expectations, future earnings and revenue growth, along with sector strength, indicate potential for price targets of $82.63 and $92.68. Read the full article on Seeking AlphaSeeking Alpha • Mar 04
Henry Schein: An Industry Leader That Offers Some Upside From Here
Summary Henry Schein is the world's largest provider of healthcare products and services for office-based dental and medical practitioners, showing consistent growth through acquisitions. Despite a 3% dip in shares, management's 2025 guidance indicates continued growth, justifying a bullish stance on the stock. The firm reported a 5.8% revenue increase in Q4 2024, driven by organic growth and acquisitions, with significant improvements in net income and operating cash flow. Henry Schein's market leadership and strategic acquisitions across various healthcare segments make it a solid investment, warranting a soft 'buy' rating. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
Henry Schein: The Kind Of Business I Like But No Margin Of Safety Now
Summary Although the U.S. stock market is currently 6.9% overvalued, according to Morningstar's analysts as of December 6, 2024, there could be opportunities in undervalued sectors like healthcare. Henry Schein is a candidate surfaced by a screen in this sector. It has many characteristics that I like in companies: easy-to-understand business, and profitable, among many others. There are some short-term headwinds that investors must be aware of but not overly concerned about. No investment is so good that it is worth buying at any price, and that applies to Henry Schein, which is currently overvalued. Read the full article on Seeking AlphaSeeking Alpha • Nov 20
Henry Schein: Another Day, Another Purchase
Summary Henry Schein announced the acquisition of Acentus, a small medical product supplier, to expand its homecare medical products platform despite recent underperformance in cash flow metrics. The CGM market, where Acentus operates, is expected to grow significantly, making the acquisition strategically sound, though financial benefits remain uncertain without disclosed terms. Despite revenue growth from acquisitions, Henry Schein's profitability metrics have declined, raising concerns about its ability to meet its revised 2024 revenue and profit targets. While Henry Schein shows potential for cost savings and slight undervaluation, persistent profitability issues and investor skepticism warrant only a cautious 'buy' rating, subject to future performance. Read the full article on Seeking Alpha
新しいナラティブ • Aug 25
Critical Acquisitions And High-Growth Product Expansion Set To Transform Dental Giant
Expansion into high-growth products and strategic acquisitions aimed at increasing gross margins through improved integration and efficiency.Seeking Alpha • May 23
Henry Schein: Acquisition Strategy Isn't Pulling Its Economic Weight
Summary Henry Schein, Inc. came in with flat revenue growth in Q1 FY'24, with most expansion coming from acquisitions. The company's capital allocation strategy, focused on acquisitions, is not creating economic value for shareholders in my view. Based on my analysis, the company's performance does not justify a higher valuation. Read the full article on Seeking Alpha株主還元
| HSIC | US Healthcare | US 市場 | |
|---|---|---|---|
| 7D | 2.0% | -2.8% | -0.8% |
| 1Y | 3.6% | 14.6% | 27.1% |
業界別リターン: HSIC過去 1 年間で14.6 % の収益を上げたUS Healthcare業界を下回りました。
リターン対市場: HSICは、過去 1 年間で27.1 % のリターンを上げたUS市場を下回りました。
価格変動
| HSIC volatility | |
|---|---|
| HSIC Average Weekly Movement | 3.6% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: HSIC 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: HSICの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1932 | 25,000 | Fred Lowery | www.henryschein.com |
ヘンリ・シャイン・インクは、世界中の歯科・医科開業医にヘルスケア製品とサービスを提供している。グローバル流通・付加価値サービス部門、グローバル専門製品部門、グローバル技術部門を通じて事業を展開している。グローバル流通・付加価値サービス部門は、感染制御製品、ハンドピース、予防薬、印象材、コンポジットレジン、麻酔薬、歯、石こう、アクリル、咬合器、研磨剤、PPE製品、ブランドおよびジェネリック医薬品、ワクチン、外科用製品、診断テスト、歯科用チェア、デリバリーユニットおよびライト、デジタルデンタルラボラトリー、X線用品および機器、ハイテクおよびデジタル修復機器を流通させるほか、機器の修理サービス、ノンリコースベースの金融サービス、開業医向けの継続教育サービス、コンサルティング、その他のサービスを提供している。また、自社ブランドによる消耗品の販売も行っている。グローバル・スペシャリティ・プロダクツ部門は、歯科用インプラントおよび生体材料製品、歯内療法、歯列矯正、整形外科用製品、その他のヘルスケア関連製品およびサービスの製造、マーケティング、販売に従事している。グローバル・テクノロジー部門は、診療管理ソフトウェア、e-サービス、その他医療従事者向けに販売する製品の開発・販売に携わっている。同社は、歯科診療所、検査室、医師診療所、外来手術センター、政府機関、施設医療クリニック、在宅医療プロバイダー、その他の代替医療クリニックにサービスを提供している。は1932年に設立され、ニューヨーク州メルビルに本社を置いている。
Henry Schein, Inc. 基礎のまとめ
| HSIC 基礎統計学 | |
|---|---|
| 時価総額 | US$8.37b |
| 収益（TTM） | US$395.00m |
| 売上高(TTM) | US$13.38b |
21.4x
PER（株価収益率0.6x
P/SレシオHSIC は割高か？
公正価値と評価分析を参照収益と収入
| HSIC 損益計算書（TTM） | |
|---|---|
| 収益 | US$13.38b |
| 売上原価 | US$9.21b |
| 売上総利益 | US$4.18b |
| その他の費用 | US$3.78b |
| 収益 | US$395.00m |
直近の収益報告
Mar 28, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 3.47 |
| グロス・マージン | 31.19% |
| 純利益率 | 2.95% |
| 有利子負債／自己資本比率 | 70.6% |
HSIC の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 21:37 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/28 |
| 年間収益 | 2025/12/27 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Henry Schein, Inc. 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。33
| アナリスト | 機関 |
|---|---|
| Jeffrey Johnson | Baird |
| Lawrence Marsh | Barclays |
| Glen Santangelo | Barclays |